정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1465 | Active, not recruiting | Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients | Vaccine Adverse Reaction | Biological: Coronavac | Phase 4 | Hospital do Rim e Hipertensao | OTHER | 3371 | All | 18 Years ~ 100 Years | Hospital do Rim - Fundacao Oswaldo Ramos, Sao Paulo, Brazil |
| 1464 | Recruiting | Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine | Covid19 | Biological: IIBR-100, low dose (prime) Biological: IIBR-100 medium dose (prime) Biological: IIBR-100 high-dose (prime) Biological: IIBR-100 low-dose (prime-boost) Other: Saline Placebo (single) Other: Saline Placebo (double) Biological: IIBR-100 medium-dose (prime-boost) Biological: IIBR-100 high-dose (prime-boost) Biological: IIBR-100 top-dose (prime-boost) |
Phase 2 | Israel Institute for Biological Research (IIBR) | OTHER_GOV | 1040 | All | 18 Years ~ 85 Years | Assuta - University Hospital, Ashdod, Israel Barzilai MC, Ashkelon, Israel Rambam MC, Haifa, Israel Hadassah Medical Center, Jerusalem, Israel Meir MC, Kfar Saba, Israel Rabin MC, Petach Tikva, Israel Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel Sourasky MC, Tel Aviv, Israel |
| 1463 | Not yet recruiting | Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of HLX71 (Recombinant Human Angiotensin-converting Enzyme 2-Fc Fusion Protein for COVID-19) in Healthy Adult Subjects | COVID 19 | Drug: HLX71 Other: Placebo |
Phase 1 | Hengenix Biotech Inc | INDUSTRY | 40 | All | 18 Years ~ 65 Years | |
| 1462 | Not yet recruiting | Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection | 2019-nCoV | Drug: ASC09/ritonavir group Drug: lopinavir/ritonavir group |
Not Applicable | First Affiliated Hospital of Zhejiang University, Ascletis Pharmaceuticals Co., Ltd. | OTHER | 160 | All | 18 Years ~ 75 Years | |
| 1461 | Not yet recruiting | Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS | Influenza, Human | Drug: AVM0703 Drug: Placebo |
Phase 1 | AVM Biotechnology LLC, Medpace, Inc. | INDUSTRY | 16 | All | 18 Years | |
| 1460 | Active, not recruiting | Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19 | Covid19 | Drug: Silmitasertib Drug: SOC |
Phase 2 | Chris Recknor, MD | INDUSTRY | 20 | All | 18 Years | Center for Advanced Research and Education, Gainesville, Georgia, United States |
| 1459 | Not yet recruiting | Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild COVID-19 | Covid19 | Biological: AD17002 Biological: Placebo (Formulation buffer) |
Phase 2 | Advagene Biopharma Co. Ltd. | INDUSTRY | 30 | All | 20 Years ~ 70 Years |